Adrenal Hyperplasia Articles & Analysis
3 news found
Citrine also recently announced two strategic partnerships that will allow the company exclusive rights to develop, register, and commercialize Alkindi® for pediatric congenital adrenal hyperplasia (CAH) patients and Efmody® for adolescent and adult CAH patients—both hydrocortisone treatments—in Greater China. ...
RareStone also recently announced two strategic partnerships that will allow the company exclusive rights to develop,register,and commercialize Alkindi®for pediatric congenital adrenal hyperplasia (CAH) patients and Efmody®for adolescent and adult CAH patients—both hydrocortisone treatments—in Greater China. ...
Citrine also recently announced a strategic partnership that will allow the company exclusive rights to develop, register, and commercialize Alkindiv®—the first clinically validated pediatric treatment for congenital adrenal hyperplasia—in the Greater China market. Citrine is headquartered in Shanghai and has other offices in Beijing, China and ...